Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Eli Lilly and Company
LY-404187
Другие языки:

    LY-404187

    Подписчиков: 0, рейтинг: 0
    LY-404187
    LY-404187.svg
    Clinical data
    Other names LY-404,187; N-2-[4-(4-cyanophenyl)phenyl]propyl-2-propanesulfonamide
    ATC code
    • none
    Legal status
    Legal status
    Identifiers
    • N-[2-(4'-cyanobiphenyl-4-yl)propyl]propane-2-sulfonamide
    CAS Number
    ChemSpider
    UNII
    CompTox Dashboard (EPA)
    Chemical and physical data
    Formula C19H22N2O2S
    Molar mass 342.46 g·mol−1
    3D model (JSmol)
    • N#Cc2ccc(cc2)-c1ccc(C(C)CNS(=O)(=O)C(C)C)cc1
    • InChI=1S/C19H28N2O2S/c1-14(2)24(22,23)21-13-15(3)17-8-10-19(11-9-17)18-6-4-16(12-20)5-7-18/h4-7,14-15,17,19,21H,8-11,13H2,1-3H3 ☒N
    • Key:AIALBPYHYGYYRB-UHFFFAOYSA-N ☒N
     ☒NcheckY (what is this?)  (verify)

    LY-404187 is an AMPA receptor positive allosteric modulator which was developed by Eli Lilly and Company. It is a member of the biarylpropylsulfonamide class of AMPA receptor potentiators.

    LY-404187 has been demonstrated to enhance cognitive function in animal studies, and has also shown effects suggesting antidepressant action as well as having possible application in the treatment of schizophrenia, Parkinson's disease and ADHD. These effects appear to be mediated through multiple mechanisms of action secondary to AMPA receptor potentiation, with a prominent effect seen in research being increased levels of BDNF in the brain. It may therefore be continued on to human trials, although Eli Lilly has developed a whole family of biarylpropylsulfonamide derivatives and it is unclear at this stage which compound is most likely to be selected for further development.

    See also



    Новое сообщение